Skip to main content

Table 1 Selected demographic and clinical characteristics of 843ADNI participants

From: Genome-wide network-based pathway analysis of CSF t-tau/Aβ1-42 ratio in the ADNI cohort

  CN
(N = 199)
SMC
(N = 85)
EMCI
(N = 239)
LMCI
(N = 207)
AD
(N = 113)
P-value
Age (years) 74.4 (5.79) 72.0(5.48) 71.4(7.30) 72.4(7.62) 75.2 (8.19) p < 0.001
Women* 96(48%) 50(59%) 102(43%) 83(40%) 45(40%) 0.002*
Education (years) 16.2 (2.82) 16(2.79) 16.2(2.84) 16.4(2.53) 16.4(2.56) 0.764
APOE e4 allele present 47(24%) 31(36%) 99 (41%) 112(54%) 74 (65%) p < 0.001
CDR-SOB 0.04(0.14) 0.08(0.18) 1.27(0.77) 1.65(0.94) 4.53 (1.70) p < 0.001
Mini mental status examination 29.1(1.18) 29.0(1.2) 28.3(1.62) 27.5(1.75) 23.1 (2.05) p < 0.001
Logical memory immediate
recall
14.42(3.00) 14.44(3.34) 11.09(2.68) 7.18(3.06) 4.15 (2.70) p < 0.001
Logical memory delayed
recall
13.34(3.13) 13.29(3.31) 8.97(1.73) 3.94 (2.7) 1.52 (1.80) p < 0.001
t-tau/Aβ1-42Ratio
(i.e., QT for GWAS)
0.40 (0.27) 0.37(0.24) 0.50(0.45) 0.70(0.47) 0.98 (0.49) p < 0.001
  1. AD Alzheimer’s disease, ADNI Alzheimer’s Disease Neuroimaging Initiative, CDR–SOB clinical dementia rating–sum of boxes, CN cognitively normal, SMC significant memory concern, EMCI early mild cognitive impairment, LMCI late mild cognitive impairment. Number (%) or mean (s.d.) was shown in each entry. P-values were assessed due to significant differences between diagnosis groups, which computed using one-way ANOVA (*except for gender using chi-square test)